Sascha Troschke‐Meurer

Author

Universitätsmedizin Greifswald ORCID

Also Known As

S Troschke-Meurer, S. Troschke-Meurer, Sascha Troschke-Meurer, Sascha Troschke‐Meurer

Publications

392

Citations

H-Index

Concepts

All Affiliations

Universitätsmedizin Greifswald St Anna Children's Hospital University of Rostock University Hospital Southampton NHS Foundation Trust Schneider Children's Medical Center

About

Sascha Troschke‐Meurer is an author at Universitätsmedizin Greifswald specializing in immunology, medicine, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	70
2	Immunology	4	4	70
3	Health Sciences	1	1	20
4	Cell Biology	1	1	14
5	Cellular Therapies	1	1	14

Sascha Troschke‐Meurer

Publications

309

Citations

H-Index

Page 1

	Year	Citations
PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD<sub>2</sub> antibody ch14.18/CHO Nikolai Siebert, Maxi Zumpe, Madlen Jüttner, OncoImmunology	2017	63
Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD<sub>2</sub> antibody ch14.18/CHO show higher ADCC levels and improved event-free survival Nikolai Siebert, Christian Fuglesang S. Jensen, Sascha Troschke‐Meurer, OncoImmunology	2016	55
Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells Christin Riess, Katharina del Moral, Adina Fiebig, Cell Death and Disease	2022	26
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma Sascha Marx, Fabian Wilken, Isabel Viola Wagner, Journal of Neuro-Oncology Neuro-oncologyGliomaPromising Immunotherapeutic ApproachImmunologyMalignant Glioma	2020	24
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study Holger N. Lode, Karoline Ehlert, Stephanie Huber, British Journal of Cancer	2023	21
Randomized use of anti-GD<sub>2</sub> antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial. Holger N. Lode, Dominique Valteau‐Couanet, Juliet C. Gray, Journal of Clinical Oncology ImmunologyImmunotherapeuticsPharmacotherapyImmunotherapyOncology	2019	20
Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2 Sascha Troschke‐Meurer, Nikolai Siebert, Madlen Marx, OncoImmunology	2019	20
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial Nikolai Siebert, Sascha Troschke‐Meurer, Madlen Marx, Cancers	2018	19
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment Christian Seitz, Tim Flaadt, Markus Mezger, Frontiers in Immunology	2021	19
Inflammatory response and treatment tolerance of long‐term infusion of the anti‐GD<sub>2</sub> antibody ch14.18/CHO in combination with interleukin‐2 in patients with high‐risk neuroblastoma Kiraz Ceylan, Luciana J. Jahns, Bjoern N. Lode, Pediatric Blood & Cancer	2018	16

Page 1